China Shineway Pharmaceutical's (HKG:2877) attributable profit fell 13% to 840.1 million yuan in 2024 from 969.5 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.
Earnings per share at the traditional Chinese medicine manufacturer fell to 1.11 yuan from 1.28 yuan in the previous year.
Revenue declined 16% to 3.78 billion yuan from 4.52 billion yuan a year earlier.
The company declared its first interim dividend of 0.36 yuan per share, payable May 20 to shareholders on record as of May 7.
Shares plunged 8% during Friday's afternoon trading.